CL2014002631A1 - Anticuerpos anti - hla - b*27 y usos de estos - Google Patents
Anticuerpos anti - hla - b*27 y usos de estosInfo
- Publication number
- CL2014002631A1 CL2014002631A1 CL2014002631A CL2014002631A CL2014002631A1 CL 2014002631 A1 CL2014002631 A1 CL 2014002631A1 CL 2014002631 A CL2014002631 A CL 2014002631A CL 2014002631 A CL2014002631 A CL 2014002631A CL 2014002631 A1 CL2014002631 A1 CL 2014002631A1
- Authority
- CL
- Chile
- Prior art keywords
- hla antibodies
- hla
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618969P | 2012-04-02 | 2012-04-02 | |
| US201361778703P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002631A1 true CL2014002631A1 (es) | 2015-01-16 |
Family
ID=48093122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002631A CL2014002631A1 (es) | 2012-04-02 | 2014-09-30 | Anticuerpos anti - hla - b*27 y usos de estos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9790273B2 (https=) |
| EP (1) | EP2834272B1 (https=) |
| JP (1) | JP6320993B2 (https=) |
| KR (1) | KR20150003256A (https=) |
| CN (1) | CN104169302A (https=) |
| AR (1) | AR090585A1 (https=) |
| AU (1) | AU2013243644C1 (https=) |
| BR (1) | BR112014024622A2 (https=) |
| CA (1) | CA2868907C (https=) |
| CL (1) | CL2014002631A1 (https=) |
| CO (1) | CO7121320A2 (https=) |
| EA (1) | EA201491827A1 (https=) |
| HK (1) | HK1207092A1 (https=) |
| IL (2) | IL234707A0 (https=) |
| MX (1) | MX365690B (https=) |
| MY (1) | MY171180A (https=) |
| NZ (1) | NZ700650A (https=) |
| PH (1) | PH12014502184A1 (https=) |
| SG (2) | SG11201405759UA (https=) |
| TW (1) | TWI619729B (https=) |
| UY (1) | UY34721A (https=) |
| WO (1) | WO2013152001A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN110241137A (zh) | 2012-07-27 | 2019-09-17 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CA2973641A1 (en) * | 2015-02-04 | 2016-08-11 | Universitat Zurich | Use of hla-b27 homodimers for cancer treatment |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| EP3341738A4 (en) | 2015-08-24 | 2019-02-27 | University of Cincinnati | METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES |
| WO2017044895A2 (en) * | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| AR107078A1 (es) * | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| HUE065073T2 (hu) * | 2015-12-18 | 2024-04-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2017230855B2 (en) | 2016-03-08 | 2021-05-27 | Universität Basel | HLA-B57 open conformers |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| JP7010439B2 (ja) | 2016-08-10 | 2022-01-26 | ウニヴェルズィテート チューリッヒ | ＭＨＣクラスＩａオープンコンフォーマー |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| EP3600376A1 (en) * | 2017-03-31 | 2020-02-05 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| EP4640703A3 (en) | 2017-11-14 | 2026-04-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
| KR102259473B1 (ko) | 2018-08-10 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| IL286482B2 (en) * | 2019-03-21 | 2025-01-01 | Gamida Cell Ltd | Cultured NK cell fractions for use in combination therapy |
| EP4696320A2 (en) | 2019-05-15 | 2026-02-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibody |
| CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
| JP2024515240A (ja) * | 2021-04-07 | 2024-04-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｈｃ－ｉ病の治療に使用するための組成物 |
| EP4416286A1 (en) * | 2021-10-14 | 2024-08-21 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
| US20250302956A1 (en) * | 2022-05-13 | 2025-10-02 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for modulating tcr specificity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0213824B1 (en) * | 1985-08-16 | 1995-05-24 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant-B27 |
| US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja not_active Expired - Fee Related
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1207092A1 (en) | 2016-01-22 |
| TW201343675A (zh) | 2013-11-01 |
| US9790273B2 (en) | 2017-10-17 |
| AU2013243644A1 (en) | 2014-10-23 |
| IL234707A0 (en) | 2014-11-30 |
| JP6320993B2 (ja) | 2018-05-09 |
| WO2013152001A2 (en) | 2013-10-10 |
| CN104169302A (zh) | 2014-11-26 |
| EA201491827A1 (ru) | 2015-03-31 |
| JP2015514110A (ja) | 2015-05-18 |
| KR20150003256A (ko) | 2015-01-08 |
| UY34721A (es) | 2013-10-31 |
| MY171180A (en) | 2019-09-30 |
| AU2013243644B2 (en) | 2018-02-08 |
| AR090585A1 (es) | 2014-11-26 |
| IL256716A (en) | 2018-03-29 |
| TWI619729B (zh) | 2018-04-01 |
| WO2013152001A3 (en) | 2013-12-27 |
| EP2834272B1 (en) | 2020-06-24 |
| BR112014024622A2 (pt) | 2017-08-08 |
| SG11201405759UA (en) | 2014-11-27 |
| PH12014502184A1 (en) | 2014-12-10 |
| NZ700650A (en) | 2017-02-24 |
| MX365690B (es) | 2019-06-11 |
| US20130259876A1 (en) | 2013-10-03 |
| CA2868907A1 (en) | 2013-10-10 |
| EP2834272A2 (en) | 2015-02-11 |
| MX2014011898A (es) | 2014-11-12 |
| CO7121320A2 (es) | 2014-11-20 |
| CA2868907C (en) | 2022-01-04 |
| AU2013243644C1 (en) | 2018-05-10 |
| SG10201608136SA (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002631A1 (es) | Anticuerpos anti - hla - b*27 y usos de estos | |
| IL269045A (en) | Aptamers and uses thereof | |
| CL2016001212A1 (es) | Moduladores de aplnr y usos de estos | |
| CL2015001321A1 (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| BR112015003354A8 (pt) | métodos e composições de microcápsula | |
| CL2016000981A1 (es) | Formulaciones de estrigolactona y sus usos | |
| CL2015000640A1 (es) | Variantes de hppd y métodos de uso | |
| EP2930714A4 (en) | Singing voice synthesizing system and singing voice synthesizing method | |
| PT2817338T (pt) | Moduladores de dll3 e métodos de utilização | |
| DK3363902T3 (da) | Crispr-baseret genommodifikation og -regulering | |
| EP2859439A4 (en) | CLOUD APPLICATION DEPLOYMENT | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| EP2879709A4 (en) | MODULATION OF IMMUNE REACTION | |
| EP2839005A4 (en) | MIRNA MODULATORS OF THERMOGENESIS | |
| EP2864479A4 (en) | MODULATION OF THE UBE3A ATS EXPRESSION | |
| PL2922850T3 (pl) | Związki i sposoby ich stosowania | |
| EP4144845C0 (en) | ANTISENSE COMPOUNDS AND THEIR USES | |
| SI3513806T1 (sl) | Sestava imunogena | |
| EP2983661C0 (en) | OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS | |
| EP4066849C0 (en) | DAPTOMYCIN FORMULATIONS AND THEIR USES | |
| PT2956476T (pt) | Moléculas de ligação e usos destas | |
| IL237397B (en) | Bacterial strain and a composition comprising the bacterial strain | |
| ME03029B (me) | Kompozicije koje obuhvataju vortioksetin i donepezil | |
| CO7091181A2 (es) | Compuestos heterociclicos y sus usos | |
| BR112015007217A2 (pt) | compostos e usos do composto |